CytomX Therapeutics’ $250 Million Equity Offering Strengthens Pipeline for Next-Generation Cancer Treatments
Market Chameleon (Wed, 18-Mar 7:06 AM)
CytomX's Varsetatug Masetecan Shows 32% Response Rate in Late-Line Colorectal Cancer—Phase 1 Data Highlights Emerging Potential
Market Chameleon (Mon, 16-Mar 9:53 AM)
CytomX’s 2025 Results Show Strong Financial Position as Pipeline Advances Toward Pivotal Data
Market Chameleon (Mon, 16-Mar 7:29 AM)
CytomX Schedules March 16, 2026 for Full-Year 2025 Results: Focus Sharpens on Pipeline Progress and Oncology Partnerships
Market Chameleon (Wed, 4-Mar 9:29 AM)
